Reduced CD16 levels on NK cells upon exposure to tumor antigen-specific BiKEs, in line with previous reports of CD16 loss in BiKE and therapeutic antibody approaches [30], could arguably limit NK cell responses. Here, FCGR3A is linked to neoplasm.